Guardant Health, Inc. (NASDAQ:GH) Shares Sold by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. decreased its position in shares of Guardant Health, Inc. (NASDAQ:GH) by 7.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,117 shares of the company’s stock after selling 332 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Guardant Health were worth $125,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Wellington Management Group LLP lifted its stake in shares of Guardant Health by 188.6% in the 3rd quarter. Wellington Management Group LLP now owns 10,127,528 shares of the company’s stock valued at $232,325,000 after purchasing an additional 6,618,785 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. raised its holdings in Guardant Health by 1,282.5% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,226,176 shares of the company’s stock valued at $28,128,000 after buying an additional 1,137,482 shares during the period. ARK Investment Management LLC lifted its position in Guardant Health by 233.5% in the third quarter. ARK Investment Management LLC now owns 1,512,694 shares of the company’s stock valued at $34,701,000 after buying an additional 1,059,104 shares during the last quarter. Erste Asset Management GmbH purchased a new position in Guardant Health during the third quarter worth about $21,389,000. Finally, Lord Abbett & CO. LLC acquired a new stake in shares of Guardant Health during the third quarter valued at about $15,624,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Insider Transactions at Guardant Health

In related news, Director Musa Tariq sold 2,320 shares of the company’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $35.00, for a total value of $81,200.00. Following the completion of the sale, the director now owns 2,676 shares in the company, valued at $93,660. This represents a 46.44 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders have sold 2,652 shares of company stock worth $93,192. Corporate insiders own 5.50% of the company’s stock.

Guardant Health Stock Up 2.4 %

Shares of Guardant Health stock opened at $48.12 on Friday. The firm has a market capitalization of $5.95 billion, a P/E ratio of -11.35 and a beta of 1.32. Guardant Health, Inc. has a 52 week low of $15.81 and a 52 week high of $50.89. The firm’s 50 day moving average is $39.02 and its two-hundred day moving average is $31.12.

Analyst Upgrades and Downgrades

Several research firms have recently commented on GH. Barclays began coverage on Guardant Health in a research report on Thursday, January 23rd. They set an “overweight” rating and a $60.00 price target for the company. Sanford C. Bernstein dropped their target price on Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a research report on Wednesday, October 30th. The Goldman Sachs Group boosted their price target on shares of Guardant Health from $36.00 to $49.00 and gave the stock a “buy” rating in a research note on Tuesday, January 28th. JPMorgan Chase & Co. lifted their price objective on shares of Guardant Health from $48.00 to $50.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Finally, Guggenheim reiterated a “buy” rating on shares of Guardant Health in a report on Wednesday, January 22nd. Sixteen research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $42.63.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.